Viking Holdings Ltd

Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target

There are other reasons to pay attention to Viking Therapeutics.

Wall Street Says Buy the Dip in Viking Therapeutics. Here's the Bull Case

The stock looks like a high-risk, high-reward play.

Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?

Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to report Q2 2026 results.

Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1

Viking's latest program seeks to push the envelope in weight loss efficacy.

Here's Why Viking Therapeutics Stock Surged Higher in June

Investors are growing more optimistic over the company's pipeline and the initiation of a Phase 1 trial with a new drug.

Viking Therapeutics: Updating Pipeline Potential As Oral GLP‑1s Accelerate

The Homebody Portfolio: How Much Does Retirement Cost When You Never Leave Chicago?

What does retirement look like for someone who genuinely has no desire to leave home? No snowbird condo in Florida. No Viking river cruises. No RV parked outside Yellowstone. Just Chicago. The Cubs in the summer, the museums when the weather turns, dinner at the neighborhood Italian restaurant, church on Sunday, and grandchildren across town ... The Homebody Portfolio: How Much Does Retirement Cost When You Never Leave Chicago?

Viking Therapeutics: Drugs Are In The Pipeline, But Profitability Is Still Unproven

Viking Therapeutics, Inc. is rated a Sell, has no revenue, and has no product available to the public at this time. Learn more about VKTX stock here.

Don't Buy Viking Therapeutics Stock Until You Read This

It may be too late for Viking to take on the "dark horse" role in the GLP-1 wars.

Could Viking Therapeutics Be the Next Eli Lilly?

Demand for weight loss drugs may fuel growth for more than one player.